Evidence map›Paper›PMID 41839977›Full record

ArticleScientific reports2026

Cardiac phenotype in hereditary transthyretin amyloidosis: correlations between fibril types and 99mTc-DPD uptake.

Viktor Löfbacka, Jonas Wixner, Per Westermark, Justina Damjanovic Vesterlund, Intissar Anan, Björn Pilebro

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Viktor LöfbackaHeart Centre, Department of Clinical Medicine, Umeå University, Umeå, Sweden. viktor.lofbacka@umu.se.
Jonas WixnerDepartment of Clinical Medicine, Umeå University, Umeå, Sweden.
Per WestermarkDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Justina Damjanovic VesterlundDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Intissar AnanDepartment of Clinical Medicine, Umeå University, Umeå, Sweden.
Björn PilebroHeart Centre, Department of Clinical Medicine, Umeå University, Umeå, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Variant transthyretin amyloidosis is a systemic disease. In Sweden, the Val30Met variant is the most prevalent. Val30Met presents in two phenotypes: an early-onset form dominated by polyneuropathy and a late-onset form frequently accompanied by cardiomyopathy. These phenotypes are associated with two amyloid fibril types. Type A fibrils, contain both fragmented and full-length transthyretin, whereas type B fibrils contain only full-length transthyretin. Fibril type has been linked to differences in cardiac tracer uptake on 99mTc-DPD scintigraphy. A total of 152 patients with confirmed variant transthyretin amyloidosis evaluated at Umeå University Hospital, Sweden, were included. Age at disease onset and cardiac involvement, investigated by echocardiography, Troponin-T, and NT-proBNP, were assessed in relation to fibril type in abdominal fat and scintigraphic findings. Eighty-five patients had type A fibrils and sixty-seven had type B fibrils. Type A patients were older at diagnosis and had pathologic scintigraphies and more severe cardiac involvement. A subset of type B patients (15%) exhibited cardiac tracer uptake and had cardiac characteristics and age at disease onset similar to those with type A fibrils. Even though there was a strong correlation with findings in abdominal fat pad biopsies, results from 99mTc-DPD scintigraphy correlated better with clinical phenotype.

Indexed as

AmyloidAmyloid Neuropathies, FamilialCardiomyopathiesOrganotechnetium CompoundsPrealbuminAdultAgedDiphosphonatesEchocardiographyFemaleHumansMaleMiddle AgedPhenotypeRadionuclide ImagingAmyloidDiphosphonatesOrganotechnetium CompoundsPrealbumintechnetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid99mTc-DPDCardiomyopathyfibril typeTransthyretin amyloidosisVal30Met

Identifiers

PMID41839977
PMCPMC12996490

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.